The Patent Finder

Quest Diagnostics Investments Incorporated

412 patents currently held · Updated Nov 19, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 23 name spellings.

186
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 9 fees due Dec 11 to 27, 2026 · next Dec 11
  • 3 fees due Feb 4 to 20, 2027 · next Feb 4
  • 4 fees due Mar 10 to 26, 2027 · next Mar 10
  • 5 fees due Apr 1 to 17, 2027 · next Apr 1
  • 11 fees due May 3 to 28, 2027 · next May 3
  • 11 fees due Jun 1 to 30, 2027 · next Jun 1
  • 10 fees due Jul 2 to 30, 2027 · next Jul 2
  • 4 fees due Aug 2 to 27, 2027 · next Aug 2
  • 2 fees due Sep 12 to 24, 2027 · next Sep 12
  • 7 fees due Oct 9 to 23, 2027 · next Oct 9
  • 3 fees due Nov 5 to 14, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 21, 2026
  • 1 term has ended since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,521,213Sample processing for nucleic acid amplification
In force
 · USPTO record
In forceUSPTO record
US 7,638,307Sample processing for nucleic acid amplification
In force
 · USPTO record
In forceUSPTO record
US 7,820,388Cystic fibrosis transmembrane conductance regulator gene mutations
In force
 · USPTO record
In forceUSPTO record
US 8,124,345Cystic fibrosis transmembrane conductance regulator gene mutations
In force
 · USPTO record
In forceUSPTO record
US 8,753,817Cystic fibrosis transmembrane conductance regulator gene mutations
In force
 · USPTO record
In forceUSPTO record
US 9,410,203Cystic fibrosis transmembrane conductance regulator gene mutations
In force
 · USPTO record
In forceUSPTO record
US 9,909,183Cystic fibrosis transmembrane conductance regulator gene mutations
In force
 · USPTO record
In forceUSPTO record
US 10,501,799Cystic fibrosis transmembrane conductance regulator gene mutations
In force
 · USPTO record
In forceUSPTO record
US 11,447,826Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations
In force
 · Low confidence
In forceLow confidence
US 8,013,186Haloalkyl Containing Compounds as Cysteine Protease Inhibitors
In force
 · High confidence
In forceHigh confidence
10 of 412 patents shown.
Pro members see all 412.
Pro members: see all 412 patents
Also on record, not counted in the 412: 1 patent in force now held by others · 42 lapsed for an unpaid fee · 75 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

55 pending · 37 abandoned · 37 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited